Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update

Author(s): Yi-dong Wang, Zhen-jie Liu, Jun Ren, Mei-Xiang Xiang*

Journal Name: Current Vascular Pharmacology

Volume 16 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.

Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.

Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 26 January, 2018
Page: [114 - 124]
Pages: 11
DOI: 10.2174/1570161115666170413145705
Price: $65

Article Metrics

PDF: 91
HTML: 19
PRC: 1